Benign prostatic hyperplasia. Part 2--management
- PMID: 18219042
- PMCID: PMC2213816
- DOI: 10.1136/bmj.39433.670718.AD
Benign prostatic hyperplasia. Part 2--management
Conflict of interest statement
Competing interests: None declared.
Figures


Comment in
-
Benign prostatic hyperplasia: alpha1 adrenoreceptor antagonists and cataract surgery.BMJ. 2008 Feb 9;336(7639):291. doi: 10.1136/bmj.39479.506933.3A. BMJ. 2008. PMID: 18258939 Free PMC article. No abstract available.
Similar articles
-
[Modern pharmacotherapy of benign prostatic hyperplasia].Pol Merkur Lekarski. 2005 Nov;19(113):710-5. Pol Merkur Lekarski. 2005. PMID: 16498818 Review. Polish.
-
Optimising the medical management of benign prostatic hyperplasia.Eur Urol. 2004 Apr;45(4):411-9. doi: 10.1016/j.eururo.2003.10.016. Eur Urol. 2004. PMID: 15041103 Review. No abstract available.
-
Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.BJU Int. 2004 Sep;94(5):738-44. doi: 10.1111/j.1464-410X.2004.05022.x. BJU Int. 2004. PMID: 15329091 Review.
-
Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Curr Urol Rep. 2008 Jul;9(4):291-4. doi: 10.1007/s11934-008-0051-y. Curr Urol Rep. 2008. PMID: 18765128 Review.
-
A current review of medical therapy for benign prostatic hyperplasia.J Am Osteopath Assoc. 2004 Feb;104(2 Suppl 2):S11-6. J Am Osteopath Assoc. 2004. PMID: 15038398
Cited by
-
Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies.Sci Rep. 2025 Jun 20;15(1):20118. doi: 10.1038/s41598-025-04267-y. Sci Rep. 2025. PMID: 40541965 Free PMC article.
-
Benign prostatic hyperplasia: alpha1 adrenoreceptor antagonists and cataract surgery.BMJ. 2008 Feb 9;336(7639):291. doi: 10.1136/bmj.39479.506933.3A. BMJ. 2008. PMID: 18258939 Free PMC article. No abstract available.
-
Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH).Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231155000. doi: 10.1177/15330338231155000. Technol Cancer Res Treat. 2023. PMID: 36794408 Free PMC article.
-
Disease identification based on ambulatory drugs dispensation and in-hospital ICD-10 diagnoses: a comparison.BMC Health Serv Res. 2013 Oct 31;13:453. doi: 10.1186/1472-6963-13-453. BMC Health Serv Res. 2013. PMID: 24171918 Free PMC article.
References
-
- American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH) www.auanet.org/guidelines/bph.cfm (updated 2006).
-
- European Association of Urology. Guidelines on benign prostatic hyperplasia. www.uroweb.org/fileadmin/user_upload/Guidelines/11%20BPH.pdf (updated 2004).
-
- Helfand M, Muzyk T, Garzatto M. Benign prostatic hyperplasia (BPH). Management in primary care—screening and therapy Department of Veterans Affairs Health Services Research and Development. 2007. www1.va.gov/hsrd/publications/esp/BPH-2007.pdf - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical